CellCentric

CellCentric is a clinical-stage biopharmaceutical company with a science-driven and patient-focused mission. Its drug inobrodib is a first-in-class p300/CBP inhibitor being developed for the treatment of multiple myeloma and other specific cancers. The company was co-founded with Prof. Azim Surani, a pioneer of cell fate control research at the Gurdon Institute, University of Cambridge.

CellCentric is built on the science of co-founder Azim Surani, Ph.D., of the Gurdon Institute, University of Cambridge. As a pioneer of cell fate control research, Dr. Surani discovered and described an inherited code, beyond DNA, that instructs cell function and fate. CellCentric investigated over 50 potential drug targets for new cancer therapies, with multiple early medicinal chemistry programs including against methyltransferases and deubiquitinases. Through this effort, they licensed an arginine methyltransferase program to Takeda Pharmaceuticals. CellCentric's research evolved to concentrate on twin transcription co-activation proteins p300 and CBP, which drive the expression of genes important in certain cancers, including MYC and IRF4. Inobrodib has been evaluated in over 500 patients across Phase I/II clinical studies in both solid tumors and hematologic malignancies. Trial sites are active across the US, UK and EU.

1. CellCentric – The p300/CBP inhibitor company
2. About us – CellCentric
3. Our story – CellCentric